167 related articles for article (PubMed ID: 27629291)
1. Study of apoptosis-related interactions in colorectal cancer.
Arora H; Qureshi R; Rizvi MA; Shrivastava S; Parihar MS
Tumour Biol; 2016 Nov; 37(11):14415-14425. PubMed ID: 27629291
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer.
Katsumata K; Sumi T; Tomioka H; Aoki T; Koyanagi Y
Int J Clin Oncol; 2003 Dec; 8(6):352-6. PubMed ID: 14663636
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
[TBL] [Abstract][Full Text] [Related]
5. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis.
Mamoori A; Wahab R; Islam F; Lee K; Vider J; Lu CT; Gopalan V; Lam AK
Hum Pathol; 2018 Jan; 71():145-156. PubMed ID: 29104111
[TBL] [Abstract][Full Text] [Related]
7. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53.
Kraus A; Gross MW; Knuechel R; Münkel K; Neff F; Schlegel J
J Neurosurg; 2000 Nov; 93(5):863-72. PubMed ID: 11059670
[TBL] [Abstract][Full Text] [Related]
9. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype.
Slattery ML; Wolff E; Hoffman MD; Pellatt DF; Milash B; Wolff RK
Genes Chromosomes Cancer; 2011 Mar; 50(3):196-206. PubMed ID: 21213373
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
13. Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
Stebbing J; Bullock AJ
Clin Cancer Res; 2024 May; 30(10):2005-2007. PubMed ID: 38470499
[TBL] [Abstract][Full Text] [Related]
14.
Zhu J; Cui K; Cui Y; Ma C; Zhang Z
DNA Cell Biol; 2020 May; 39(5):747-755. PubMed ID: 32182129
[TBL] [Abstract][Full Text] [Related]
15. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
17. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
18. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
19. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
Du L; Kim JJ; Shen J; Chen B; Dai N
Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
